MetaCap

Biohaven (BHVN) vs Vera Therapeutics (VERA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biohaven (BHVN) has outperformed Vera Therapeutics (VERA) over the past year, gaining 27.9% versus a loss of 10.6%. Biohaven is the larger company by market cap ($1.87 billion vs $1.84 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BHVN+27.86%VERA-10.58%
+101%+40%-22%
Nov 21, 20251 yearNov 20, 2026
BHVN+73.63%VERA+15.73%
+752%+319%-114%
Sep 19, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BHVN versus VERA key metrics
MetricBHVNVERA
Share price$12.39$25.45
Market cap$1.87B$1.84B
1-day change-9.23%-4.86%
YTD return+9.74%-49.74%
1-year return+27.86%-10.58%
5-year return—-15.17%
EPS (TTM)$-3.77$-5.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-738.82M$-299.62M
52-week high$18.24$56.05
52-week low$8.03$25.08
Distance from 52-week high-32.07%-54.59%
Analyst consensusbuystrong_buy
Avg. price target upside+102.82%+180.39%
Average volume3.24M1.95M
Shares outstanding151.06M72.30M
Employees274362
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BHVN has outperformed VERA by 38.4 percentage points over the past year.

About Biohaven

BHVN stock →

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees

About Vera Therapeutics

VERA stock →

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees

BHVN vs VERA FAQ

Which is bigger, Biohaven or Vera Therapeutics?

Biohaven (BHVN) is larger, with a market capitalization of $1.87B compared with $1.84B for Vera Therapeutics (VERA).

Which stock has performed better over the past year, BHVN or VERA?

BHVN returned +27.86% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.

Are Biohaven and Vera Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons